Stay updated on Eli Lilly and Company Press Releases

Sign up to get notified when there's something new on the Eli Lilly and Company Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Eli Lilly and Company Press Releases page

  1. Check
    3 days ago
    Change Detected
    Summary
    The press-release list adds announcements about Phase 3b findings for Taltz and Zepbound and Lilly’s dermatology presentations at Fall Clinical 2026. It removes earlier releases about Lilly’s access commitment for diabetes and obesity medicines and FDA approval of Olumiant for certain pediatric patients.
    Difference
    6%
    Check dated 2026-10-10T16:53:51.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The latest releases now cover Jaypirca’s expanded FDA indication, new findings for Lilly’s obesity and diabetes medicines, and an access commitment. Older releases about other drug approvals, clinical data, manufacturing, and corporate activity have dropped off the list.
    Difference
    7%
    Check dated 2026-10-03T16:45:51.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Adds three new press releases: FDA approvals for Olumiant in pediatric alopecia areata and Onswik insulin, and a Houston manufacturing site announcement. Removes several older items related to Mounjaro and Zepbound matters and retatrutide lawsuits from the press releases list.
    Difference
    8%
    Check dated 2026-09-26T18:52:37.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    New press releases about Inluriyo with Verzenio and upcoming EASD 2026 data were added to the press releases list. Older items, including Q2 2026 results and other older recognitions, were removed from the listing.
    Difference
    8%
    Check dated 2026-09-19T20:06:20.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    A new press release announcing the completion of Lilly's acquisition of AtaiBeckley has been added, signaling a strategic expansion into neuropsychiatry. Content related to obesity trial results from the TRIUMPH studies was removed.
    Difference
    2%
    Check dated 2026-09-12T19:41:59.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    New entries announce Lilly's participation in the Morgan Stanley Global Healthcare Conference, new Phase 3b data on Taltz and Zepbound, and the Merida Biosciences acquisition. Older items—Q2 2026 results date, AtaiBeckley acquisition, and AAIC 2026 coverage—were removed from the press releases list.
    Difference
    8%
    Check dated 2026-09-05T18:41:57.000Z thumbnail image

Stay in the know with updates to Eli Lilly and Company Press Releases

Enter your email address, and we'll notify you when there's something new on the Eli Lilly and Company Press Releases page.